ديجيتال فابلت

الوسم: hormone therapy

  • New Insight Links Estrogen to Alzheimer’s Risk


    Credit: Unsplash+

    Estrogen use after menopause has a complex medical history. It was once widely prescribed but later became controversial due to studies linking it to increased risks of dementia, cancer, and cardiovascular issues.

    Recent research from Stanford Medicine suggests that a specific form of hormone therapy may tell a different story. Women who used only estrogen showed fewer physical indicators of Alzheimer’s disease in their brains after death and were less often diagnosed with dementia during their lives.

    It’s important to distinguish between estrogen-only therapy and other hormone treatments. Typically, estrogen alone is prescribed to women who’ve had a hysterectomy, meaning they no longer have a uterus.

    Women with uteruses usually receive additional hormones, such as progesterone, along with estrogen. This combination is to protect the uterine lining and reduce cancer risk.

    The new findings primarily concern women who used estrogen-only therapy. Not all hormone treatments showed benefits, making this distinction significant.

    The investigation into hormones and Alzheimer’s is especially relevant because women make up roughly two-thirds of Alzheimer’s cases, and estrogen influences many parts of the body, including the brain.

    Alzheimer’s progressively damages nerve cells involved in memory, reasoning, and daily functioning. It’s characterized by abnormal buildup of amyloid plaques outside the cells and tau protein tangles inside them.

    While diagnosing dementia clinically provides helpful information, it’s not perfect because multiple factors can cause memory problems. Conditions like strokes, other dementias, medications, depression, and temporary illnesses can all impact cognition, especially in older adults.

    Because of these complexities, Stanford researchers decided to analyze the brains directly. Led by senior author Hadi Hosseini, they examined autopsy data to assess physical signs associated with Alzheimer’s disease.

    The team reviewed data from two large databases including 21,462 individuals. They identified women whose brains had been examined after death and compared their history of menopausal hormone therapy with the amount of Alzheimer’s-related damage observed during autopsy.

    In particular, they focused on 258 women who had used estrogen-only therapy and about 2,701 women who did not use any menopausal hormone treatment. They evaluated amyloid plaques, tau tangles, and the density of amyloid deposits.

    The results favored estrogen-only users, whose brains showed significantly fewer Alzheimer’s-associated changes. Statistical analysis indicated approximately a 35% reduction in the likelihood of Alzheimer’s pathology among them.

    Beyond autopsy findings, the researchers examined data collected during the women’s lives, including dementia diagnoses, memory assessments, and ability to perform daily activities.

    Women who used estrogen alone had a 39% lower chance of having been diagnosed with dementia. They also performed better on memory tests and could manage everyday tasks more effectively.

    These findings persisted even after adjusting for several known risk factors like age, hypertension, education, race, and the presence of the APOE4 gene, which strongly influences Alzheimer’s risk.

    This is especially notable because previous studies on hormone therapy produced mixed results. Some observational research suggested estrogen might protect the brain, but later clinical trials cast doubt on these claims.

    The Women’s Health Initiative Memory Study (published in 2003) was influential, finding that women taking estrogen with progestin had an increased risk of dementia, especially when starting therapy later in life.

    These results significantly impacted public perceptions of menopausal hormone therapy, leading to decreased use and heightened caution from healthcare providers over the years.

    However, scientists now question whether findings from one group of women and a specific hormone regimen apply broadly. Timing of hormone initiation—close to menopause or much later—may affect outcomes. Additionally, estrogen alone might behave differently than estrogen combined with progestin.

    The Stanford study couldn’t determine the effects of combined therapy due to limited data on women using estrogen plus progestin and available brain tissue samples. It also excluded topical estrogen treatments, so results don’t necessarily apply to patches or gels.

    The women studied were generally older, averaging around 70, and many had undergone hysterectomies. The researchers noted current clinical guidelines often favor starting hormone therapy during or shortly after menopause when symptoms begin.

    The study was published on August 12, 2026, in the journal Neurology, led by Stanford Medicine researchers including Hadi Hosseini and Jennifer Bruno. It’s the first to analyze a large number of postmortem brains directly for Alzheimer’s pathology in the context of menopausal hormone use.

    This approach is valuable since autopsy findings are less influenced by subjective memory reports. Correlating physical brain changes with diagnostic and testing information strengthens the overall conclusions.

    Nonetheless, the study can’t prove causality. It didn’t randomly assign women to hormone use, so unmeasured differences might partly explain the observed association.

    Therefore, these results shouldn’t be taken as a reason to start hormone therapy solely for brain health. Hormone treatments can carry risks depending on individual health and age.

    The key takeaway is that estrogen-only therapy doesn’t necessarily fit with the old idea that menopausal hormones increase dementia risk. Instead, it may be linked to a meaningful decrease in Alzheimer’s signs in some women.

    Future research should explore different formulations, doses, onset timings, and durations to clarify these effects. If clinical trials confirm a protective benefit, physicians could consider hormone therapy not just for menopausal symptoms but also for supporting long-term brain health.

    Source: Stanford Medicine

  • Hormone Therapy May Boost Postmenopause Weight Loss in Women

    Hormone Therapy May Boost Postmenopause Weight Loss in Women

    A recent study from the Mayo Clinic suggests that combining hormone therapy with modern weight-loss medications may significantly enhance weight loss for women during and after menopause. The research indicates that this combination could potentially reshape how doctors approach obesity treatment in postmenopausal women.

    Following menopause, many women experience noticeable changes in their bodies, with weight gain being among the most common. This occurs partly because declining estrogen levels can slow the metabolism and alter fat storage processes. As a result, women often find it more challenging to shed weight and more prone to gaining it, increasing their risk for heart disease and diabetes.

    Hormone therapy, widely used to alleviate menopause symptoms like hot flashes, night sweats, and sleep disturbances, helps improve quality of life during these years. Although its effectiveness in reducing menopausal discomfort is well established, its impact on weight management has been less clear.

    Recently, the development of new weight-loss drugs, such as tirzepatide, has provided promising results. Tirzepatide helps suppress appetite and regulate blood sugar levels, leading to notable weight reduction for many users. Researchers, however, wondered if its benefits could be further amplified through additional therapies.

    To investigate this, a team studied 120 adults who had been on tirzepatide for at least 12 months. They compared the weight loss outcomes between women taking hormone therapy and those not using it. Both groups started the study with similar ages, weights, and health conditions.

    The results were impressive. Women combining hormone therapy with tirzepatide lost approximately 35% more weight than those using the medication alone. This suggests that hormone therapy might boost the drug’s effectiveness in aiding weight loss.

    The findings, published in The Lancet Obstetrics, Gynecology, & Women’s Health, imply that this dual approach could be a more effective way to manage weight and lower health risks for women after menopause. Possible reasons for this include hormone therapy’s ability to improve sleep quality, reduce menopausal discomfort, and perhaps directly support weight loss. Some early scientific evidence indicates that estrogen may enhance the appetite-suppressing effects of medications like tirzepatide.

    However, the researchers emphasize that more research is necessary. Because the study was observational, it can reveal associations but can’t definitively establish cause and effect. External factors like lifestyle choices may have influenced the results. Future randomized clinical trials are planned to better determine whether hormone therapy genuinely amplifies weight loss and improves other health outcomes, such as cardiovascular health and blood sugar control.

    This study is significant because it spotlighted an often-overlooked group—postmenopausal women—who face unique obstacles in weight management. While the findings are promising, the relatively small number of participants and the study design mean conclusions should be cautious. Nonetheless, the consistent results and substantial difference in weight loss provide a compelling reason for further investigation.

    If you’re interested in weight loss strategies, consider looking into recent studies on topics like hop extract reducing belly fat and early time-restricted eating helping with weight loss and blood pressure regulation. For additional health insights, explore recent research on simple weight-loss methods and non-invasive treatments for obesity and diabetes.

    Source: Mayo Clinic.

  • Unexpected drug combo boosts weight loss in women 50+ by 35%

    Unexpected drug combo boosts weight loss in women 50+ by 35%

    Credit: Unsplash+


    A recent study led by Mayo Clinic has discovered that a common menopause treatment might boost weight loss when combined with a popular weight-loss medication. These findings could open new avenues for better managing weight and health risks for women after menopause.

    Menopause, a natural phase in life, typically occurs in women’s late 40s or early 50s. During this time, estrogen production declines, causing symptoms like hot flashes, disrupted sleep, and mood swings.

    This hormonal change can also make it easier to gain weight, especially around the belly. Excess weight in this area raises the risk of serious conditions such as heart disease and type 2 diabetes.

    Many women opt for menopausal hormone therapy to relieve symptoms, which helps replace some of the lost estrogen. While this treatment can improve quality of life, scientists haven’t fully understood whether it also influences weight management.

    Meanwhile, new weight-loss medications have entered the market. One of these is tirzepatide, FDA-approved for people with overweight or obesity. It functions by suppressing appetite and regulating blood sugar, promoting weight reduction.

    Researchers set out to explore whether hormone therapy could enhance the effects of tirzepatide. They analyzed data from 120 adults who used the medication for at least a year.

    Some of these women were also on hormone therapy, while others were not. To ensure a fair comparison, the researchers matched the groups based on their starting conditions.

    The results revealed a notable difference: women combining hormone therapy with tirzepatide experienced approximately 35% more weight loss than those using just the medication. This substantial difference suggests potential synergy between the treatments.

    The findings appeared in The Lancet Obstetrics, Gynecology, & Women’s Health. Lead author Dr. Regina Castaneda noted that these insights might help healthcare providers develop more tailored treatment strategies for postmenopausal women.

    However, the study’s authors also acknowledged that this observational research doesn’t definitively prove that hormone therapy directly causes the increased weight loss. Other factors could be influencing the results.

    For instance, women opting for hormone therapy may also be more diligent about maintaining healthy habits, such as balanced eating and regular exercise. Additionally, symptom relief might improve sleep quality and boost motivation for lifestyle changes.

    There’s also interest in understanding how estrogen might interact with weight-loss drugs. Early evidence suggests that estrogen could enhance the appetite-suppressing effects of medications like tirzepatide, possibly explaining the greater weight loss observed with combined treatment.

    Researchers are now planning further investigations, including clinical trials, to confirm these preliminary findings. They also aim to examine whether this combination can positively impact other health indicators, such as blood sugar, cholesterol, and heart health.

    Overall, this study highlights a promising new approach to supporting women through menopause. Combining treatments could yield better results than relying on a single method.

    From an analytical standpoint, the early evidence indicates a significant and clinically relevant link between hormone therapy and weight-loss medication. Yet, due to the study’s design and small sample size, more rigorous trials are needed before healthcare providers can make firm recommendations. Nevertheless, these findings pave the way for future research and potential new therapies.

    If weight management interests you, consider exploring articles about diets that can treat fatty liver disease and obesity and hop extract and its potential to reduce belly fat in overweight individuals.

    For additional insights into weight control, see recent studies on how to curb cravings for processed foods and foods that can boost your metabolism.

    Source: Mayo Clinic.



  • Menopause Treatment & Dementia Risk: Insights from a New Study

    Menopause Treatment & Dementia Risk: Insights from a New Study

    Hormone therapy is commonly prescribed to alleviate menopausal symptoms such as hot flashes and night sweats. However, there has long been debate among scientists about whether it influences the risk of developing dementia. Recent research adds a new perspective by suggesting that a biomarker associated with Alzheimer’s disease might help identify women more susceptible to dementia when using certain hormone therapies.

    The study analyzed blood samples from 2,766 women who participated in a clinical trial between 1996 and 1999. Researchers tracked these women until 2021 to determine if initial levels of plasma p-tau217, a biomarker linked to Alzheimer’s, were connected to the development of dementia, and whether this relationship varied based on hormone therapy use.

    Plasma p-tau217 is a biological indicator of Alzheimer’s; elevated levels in the blood are associated with brain changes characteristic of the disease. The women in the study received either a placebo or two types of hormone therapy: one combining estrogen and progesterone, often prescribed for women with intact wombs, and another with estrogen alone, typically given after hysterectomy.

    Women with higher biomarker levels faced a significantly increased risk of dementia. Specifically, those with elevated p-tau217 levels at the start had roughly three times the risk. The risk was even higher among women on combined hormone therapy—about four times greater—compared to those taking a placebo or estrogen-only therapy. This heightened risk was most pronounced in women over 70, white women, and carriers of the APOE4 gene variant, which increases Alzheimer’s risk.

    Scientists believe the differences between hormone therapies may relate to how hormones interact with the brain’s biology. Estrogen is thought to protect brain cells and influence the processing of amyloid and tau proteins, both of which accumulate in Alzheimer’s. Progesterone’s role in modifying these effects is not yet fully understood.

    Prior studies from the Women’s Health Initiative, a large set of clinical trials, initially linked hormone therapy after age 65 with a doubled risk of dementia and observed that its risks outweighed potential benefits. These findings led many women to discontinue hormone therapy. More recent research shows that starting hormone treatment closer to menopause—around age 50—may not impact cognitive function significantly over a span of several years and may be relatively safe.

    However, initiating hormone therapy later in life appears to have different effects. Women who started treatment after age 65 generally experienced cognitive decline, with MRI scans indicating shrinkage in brain areas like the hippocampus, which is often affected in Alzheimer’s disease. This suggests that hormone therapy later in life could exacerbate existing brain vulnerabilities.

    The new findings reinforce previous evidence indicating that combining estrogen with progestin later in life may increase Alzheimer’s risk, unlike estrogen alone. Additionally, severe menopausal symptoms such as hot flashes and night sweats—especially when they occur late in life—are linked to higher dementia risk and often lead to hormone therapy use, which complicates the picture.

    These insights imply that hormone therapy itself doesn’t directly cause dementia. Instead, biological risk markers and individual factors—such as age at treatment onset and genetic predispositions—may determine vulnerability. Starting combined hormone therapy late in life, particularly after age 65, could raise the likelihood of cognitive decline for some women. Conversely, short-term use around menopause—less than five years—has not been associated with increased dementia risk.

    Most women are prescribed hormone therapy for a limited time to manage menopausal symptoms, which generally doesn’t elevate their risk of dementia when initiated around age 50. For those concerned about brain health, exploring additional studies on topics like vitamin B9 deficiency’s link to dementia or how cranberries might support memory could prove beneficial. Recent research also highlights that certain heartburn medications may raise dementia risk, while following diets like the MIND diet could help protect cognitive function.

    — Eef Hogervorst, The Conversation

  • New Drug Combo Shows Promise in Slowing Aggressive Prostate Cancer

    New Drug Combo Shows Promise in Slowing Aggressive Prostate Cancer

    A recent international study has revealed that combining two cancer drugs could significantly slow the progression of a particularly dangerous form of prostate cancer in certain men. Led by researchers at University College London (UCL), the study involved hundreds of patients from multiple countries.

    Published in the journal Nature Medicine, these findings offer renewed hope for patients with prostate cancer that harbors specific genetic mutations, making the disease more difficult to treat.

    Prostate cancer ranks among the most common cancers affecting men. The prostate, a small gland located below the bladder, plays a role in semen production. As men age, prostate cells can grow uncontrollably, forming tumors. Often, prostate cancer develops slowly and can be managed effectively with treatment.

    However, some cases become aggressive, spreading to areas like bones and lymph nodes. Once the cancer metastasizes, treatment becomes more challenging and the risk to life increases.

    Researchers have long sought to understand why some prostate tumors become more aggressive than others. A key clue involves a group of genes responsible for repairing damaged DNA, known as homologous recombination repair (HRR). These genes act as a cellular repair crew, fixing DNA errors that could otherwise trigger cancer. When these genes function properly, they help prevent cancer from developing. But when mutated or damaged, DNA repair is impaired, leading to faster cancer growth and spread.

    Approximately 25% of men with advanced prostate cancer carry mutations in HRR-related genes, including well-known ones like BRCA1 and BRCA2—genes also linked to breast and ovarian cancers. Other important genes, such as CHEK2 and PALB2, can also contribute. When these genes aren’t working correctly, the cancer tends to become more aggressive and less responsive to standard treatments.

    To explore new treatment options, scientists conducted the large-scale AMPLITUDE trial, a Phase III clinical study. This phase typically tests a promising treatment in a broad patient population to verify its safety and effectiveness.

    The trial included 696 men from 32 countries, all with metastatic prostate cancer who had not yet started specific treatment for this stage. The average age of participants was 68, and every participant had a mutation in an HRR gene.

    Participants were divided into two groups. One received the standard treatment, which includes abiraterone acetate and prednisone—medications that slow cancer growth by lowering male hormone levels that fuel tumor development. The other group received the same standard treatment plus niraparib, a targeted drug known as a PARP inhibitor.

    PARP inhibitors are designed to exploit weaknesses in cancer cells with DNA repair deficiencies. By blocking another repair pathway, these drugs cause cancer cells to accumulate lethal levels of DNA damage, leading to cell death. Healthy cells are less affected because their repair mechanisms remain functional.

    The study was double-blind, meaning neither the patients nor the doctors knew who received niraparib or a placebo, reducing bias and increasing the reliability of results.

    After a median follow-up of about 30.8 months, the data showed a clear benefit for those on the combination therapy. Patients taking niraparib with standard treatment had a 37% lower chance of their cancer worsening compared to those on standard therapy alone.

    The most remarkable results appeared in patients with mutations in BRCA1 or BRCA2. In this subgroup, the risk of disease progression dropped by nearly half—about 48%. This suggests that the drug combination could be especially potent for patients with these specific genetic weaknesses.

    Additionally, symptom worsening took longer in the niraparib group. Only 16% experienced significant symptom progression, compared to 34% in the placebo group. This indicates that many patients maintained their quality of life longer with the combination treatment.

    There were signs that the new therapy might boost overall survival, but longer follow-up is necessary to confirm this potential benefit.

    As with many cancer treatments, side effects were more common among patients taking niraparib. Some experienced anemia, a condition where red blood cell levels are too low, and high blood pressure was also reported more frequently. About a quarter of patients needed blood transfusions during treatment, and there were slightly more treatment-related deaths in the niraparib group, though numbers remained small. Most patients were still able to continue treatment despite these issues.

    The study underscores the importance of genetic testing in cancer care. By identifying HRR gene mutations early, clinicians can better determine which patients are most likely to benefit from targeted therapies like niraparib.

    Annually, around 1.5 million men are diagnosed with prostate cancer worldwide. In the United States alone, over 56,000 men are diagnosed each year, with roughly 12,000 deaths. Because of its prevalence, even modest advances in treatment can significantly impact public health.

    The AMPLITUDE trial was sponsored by Janssen Research and Development, part of Johnson & Johnson. These results suggest that combining genetic-driven therapies with hormone treatments could be a key step toward personalized cancer care.

    Overall, the research demonstrates that adding niraparib to standard therapy can delay disease progression in men with certain genetic forms of advanced prostate cancer. Still, potential risks and side effects should be carefully considered. More long-term studies are vital to determine if this approach improves overall survival and to identify which patients are the most suitable candidates.

    Despite the need for further research, these findings mark an important milestone in tailoring cancer treatments based on individual genetic profiles.